Benzinga | Dec 9, 2021 09:46PM EST

Ocugen, Inc. Announces U.S. FDA Acceptance Of Investigational New Drug Application To Initiate A Phase 1/2 Clinical Trial For Gene Therapy Candidate OCU400 To Treat Inherited Retinal Degeneration

* Gene therapy candidate has potential to address a large number of retinitis pigmentosa and Leber congenital amaurosis gene mutations with a single product

* Trial to start in Q1 2022 will enroll patients with mutations in NR2E3 or RHO genes